← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	3,105	-163	-5%	$162B
2	2 Eli Lilly LLY $1.12T	2,614	-57	-2%	$270B
3	3 Amgen AMGN $234B	2,435	-66	-3%	$98.3B
4	4 Becton Dickinson BDX $51.9B	1,525	-30	-2%	$61.3B
5	5 McKesson MCK $117B	1,265	-22	-2%	$41.7B
6	6 Regeneron Pharmaceuticals REGN $81.3B	1,191	+33	+3%	$76.1B
7	7 Novo Nordisk NVO $171B	1,145	+97	+9%	$22.1B
8	8 AstraZeneca AZN $256B	1,055	-7	-0.7%	$35B
9	9 Conagra Brands CAG $6.87B	890	+11	+1%	$15.1B
10	10 Lamb Weston LW $7.34B	742	+56	+8%	$13.2B
11	11 West Pharmaceutical WST $26.8B	695	+58	+9%	$24B
12	12 ResMed RMD $33.6B	677	-53	-7%	$20.9B
13	13 DELISTED CATALENT, INC. CTLT	526	+41	+8%	$12.5B
14	14 DaVita DVA $11.9B	439	-5	-1%	$6.32B
15	15 Teva Pharmaceutical Industries Limited TEVA $48.2B	438	+17	+4%	$4.95B
16	16 Embecta EMBC $359M	433	-10	-2%	$1.57B
17	17 Inspire Medical Systems INSP $2.01B	373	+33	+10%	$6.68B
18	18 BellRing Brands BRBR $1.07B	311	+29	+10%	$4.29B
19	19 Medifast MED $133M	267	-10	-4%	$1.06B
20	TWNK 20 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	264	-21	-7%	$3.42B
21	21 Opko Health OPK $1.16B	227	+8	+4%	$259M
22	22 Madrigal Pharmaceuticals MDGL $10.5B	223	+35	+19%	$3.36B
23	23 Amphastar Pharmaceuticals AMPH $1.1B	218	+7	+3%	$1.13B
24	24 Accendra Health ACH $17M	217	0	0%	$1.09B
25	25 Herbalife HLF $1.52B	210	-6	-3%	$1.72B